Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226745 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
A Phase 2 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
NCT01226745 is a Phase 2 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 340 participants.
The verdict
NCT01226745, a Phase 2 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
Study Summary
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 \[NCT01081782\]).
Interventions
- DRUG ONO-4641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01226745
The ClinicalTrials.gov registry entry for NCT01226745 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONO-4641 is the first listed.
NCT01226745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01226745 about?
NCT01226745 is a clinical study titled "Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)". The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 \[NCT01081782\]).
What is the current status of trial NCT01226745?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2010-10. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01226745?
The interventions under investigation include: ONO-4641 (DRUG).
Who is sponsoring clinical trial NCT01226745?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.